Vanda Pharmaceuticals (VNDA) Other Operating Expenses (2010 - 2026)

Vanda Pharmaceuticals has reported Other Operating Expenses for 17 years, with the latest figure at $5.1 million in Q1 2026.

• Quarterly Other Operating Expenses fell 2.41% year-over-year to $5.1 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $114.8 million (up 523.82% YoY) and the FY2025 annual result came in at $114.9 million, up 518.29% from the prior year.
• Other Operating Expenses slipped to $5.1 million in Q1 2026 per VNDA's latest filing, from $100.5 million in the prior quarter.
• Over five years, Other Operating Expenses peaked at $100.5 million in Q4 2025 and troughed at $3.4 million in Q3 2023.
• A 5-year average of $10.7 million and a median of $5.1 million in 2026 frame the typical range for Other Operating Expenses.
• The sharpest annual moves came in 2023 and 2025: Other Operating Expenses tumbled 48.6% in 2023, then surged 2213.59% in 2025.
• Over 5 years, Other Operating Expenses stood at $6.6 million in 2022, then sank by 33.31% to $4.4 million in 2023, then decreased by 1.61% to $4.3 million in 2024, then soared by 2213.59% to $100.5 million in 2025, then tumbled by 94.88% to $5.1 million in 2026.
• According to Business Quant data, Other Operating Expenses over the past three periods registered $5.1 million, $100.5 million, and $4.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.